trending Market Intelligence /marketintelligence/en/news-insights/trending/oPNJYZIDBT5OFrw8Tdtu1g2 content esgSubNav
In This List

Dr. Reddy's plaque psoriasis treatment secures US approval

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Dr. Reddy's plaque psoriasis treatment secures US approval

The U.S. Food and Drug Administration approved Dr. Reddy's Laboratories Ltd.'s new drug application for Impoyz cream for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older.

Impoyz is licensed to Encore Dermatology Inc. for commercialization of the product in the U.S.